What African HealthTech Can teach the UK
When UK HealthTech founders and investors talk about African health systems, the framing is almost always developmental. Africa as a future market. Africa as a place where simpler versions of Western products will eventually find a home. Africa as downstream.
That framing is wrong. And the cost of holding it is that you are missing some of the most important commercial and clinical innovation in global HealthTech right now.
Here is what I mean.
THREE THINGS BEING BUILT IN AFRICA THAT MATTER TO YOU
1. Prevention is the primary commercial model, not a secondary consideration.
In markets where treatment infrastructure is limited, building a commercial health product around prevention isn't an ethical choice. It's a structural necessity. The result is that a generation of African HealthTech founders have done what UK and European founders are still trying to figure out: they've built the commercial case for prevention into the product architecture from day one. They didn't retrofit prevention into a treatment-first model.
This is the founding insight of the prevention economy, and it is being stress-tested at scale in East and West Africa in ways it has never been tested in a Western health system.
2. Mobile-first health financing is creating a new model for health payment access.
The infrastructure that transformed financial inclusion across East Africa, mobile payment rails, micro-insurance, community savings groups, is now being applied directly to health financing. In Kenya and Uganda, ventures are building health savings and micro-insurance products that operate entirely on mobile infrastructure, reaching informal sector workers who are systematically excluded from every traditional health insurance model.
For UK founders thinking about health financing, equity, and access: this is not an emerging market problem. It is a design solution to a structural challenge that the NHS and private health insurers are both struggling with. The model being tested in Nairobi is more sophisticated than anything currently being piloted in London.
3. African clinical deployment evidence is crossing into global investment memos.
For the first time, I am seeing peer-reviewed evidence from clinical deployments in East and West Africa cited in HealthTech investment analyses as primary clinical evidence, not as emerging market proof points, but on equal footing with UK and US trial data.
The quality threshold has been crossed. The international HealthTech investment community is paying attention, even if the procurement community in the UK has not caught up yet.
WHAT THIS MEANS FOR UK FOUNDERS
The most immediate practical implication, if you are building in the prevention space and you have not looked at what is being deployed and validated in Africa, you are missing clinical evidence that might be directly relevant to your product thesis.
The more strategic implication, the prevention economy is not a Western innovation waiting to reach developing markets. It is being built in parallel, in some ways with more rigour, from a different and arguably more honest starting architecture. The UK HealthTech sector would benefit from learning from it, not teaching it.
And the investment implication. The founders and fund managers I follow most closely in this space are positioning ahead of a shift that has not yet been widely recognised. When it is, the early movers will have a significant advantage.
With purpose,
Sara
Founder, Well Purposed
βββββββββββββββββββββββββββββββββββββββββββββ
P.S. If you work with a healthtech founder who'd find this useful - forward it. The newsletter is free and always will be.
Responses